TXNDC9 (thioredoxin domain containing 9) functions as an oncogenic protein that promotes cancer progression through multiple mechanisms. The protein is overexpressed in various cancers including colorectal cancer, gastric cancer, hepatocellular carcinoma, and prostate cancer, where high expression correlates with poor prognosis and advanced disease stages 1 2 3. TXNDC9 operates through several key pathways: it directly interacts with MYC to enhance MYC-mediated transcriptional activation of target genes in hepatocellular carcinoma 2, activates NF-κB signaling to promote tumor cell invasion and epithelial-mesenchymal transition in gastric cancer 1, and regulates autophagy-apoptosis balance via the Nrf2 pathway contributing to chemotherapy resistance 4. In prostate cancer, TXNDC9 facilitates androgen receptor signaling under oxidative stress conditions through protein interaction exchanges involving PRDX1 and MDM2 5. The protein also provides cellular protection against UV-B-induced apoptosis through NF-κB/p65 activation in cutaneous squamous cell carcinoma 6. Clinically, TXNDC9 represents a potential therapeutic target, as its inhibition suppresses tumor growth, invasion, and enhances sensitivity to treatments like oxaliplatin and photothermal therapy 4 7.